Uppsala, Sweden, December 6th, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Almac Discovery Ltd., an independent member of the Almac Group Ltd. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint™, to identify high-quality fragment hits against a number of [...]
Continue Reading
Uppsala, Sweden, November 24th, 2011 Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University in 2006, was recognised as the fastest growing young biotech in Sweden by management consultants Deloitte at the “Technology Rising Stars” prize giving ceremony in Stockholm this week. “This result shows we are delivering valued results to [...]
Continue Reading
Uppsala, Sweden, October 11th, 2011 Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University announces that it is amongst 25 companies nominated as “Technology Rising Stars” by management consultants Deloitte. “We are delighted to be one of the 25 fastest growing new technology companies in Sweden” says Per Källblad, CEO of [...]
Continue Reading
Uppsala, Sweden, April 27th, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint™, to generate small-molecule lead compounds against undisclosed targets of therapeutic [...]
Continue Reading
Uppsala, Sweden, February 22nd, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has received a grant of up to €700 000 from the EU 7th Framework Programme to support the Company’s pioneering work in the area of influenza. In the FluCure project, Beactica will apply its proprietary fragment-based drug discovery [...]
Continue Reading
Uppsala, Sweden, February 4th, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced the publication of two key papers based on in-house research in the field-leading Journal of Medicinal Chemistry*. The papers present methodological advances in SPR biosensor-based drug discovery targeting structurally dynamic proteins, a significant challenge for the pharmaceutical industry, that have [...]
Continue Reading
Uppsala, Sweden, December 14th, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced that board member Gisela Sitbon will assume the position of Chairman and that Mr Jan Mellberg will join its Board, both effective immediately. Dr Gisela Sitbon has more than 25 years experience from the life science industry including positions as [...]
Continue Reading
Uppsala, Sweden, November 2nd, 2010 Beactica, the Swedish fragment-based drug discovery company, today announced an important move to address the need for increased data quality and higher capacity in understanding molecular interactions. Growing customer demand for solutions to ever more complex research challenges has led Beactica to invest in the world’s most sophisticated SPR biosensor [...]
Continue Reading
Uppsala, Sweden, October 12th, 2010 Beactica, the Swedish fragment-based drug discovery company, today announced the publication of three key papers in leading scientific journals*. The papers describe important work towards the discovery of novel drugs targeting Cys-loop ion channel receptors, a significant family of drug targets involved in various neurological diseases, for example epilepsy. Two [...]
Continue Reading
Uppsala, Sweden, September 3rd, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced the promotion of Dr Evert Homan to Chief Operating Officer. Evert has been with the Company since 2008 when he joined from Biovitrum. He has more than ten years experience from the international pharmaceutical industry and a broad knowledge of [...]
Continue Reading
